George Yancopoulos, Regeneron president and CSO (Brendan McDermid/Reuters/Alamy)
October 24, 2022 02:45 PM EDT
Pharma
FDA+

Re­gen­eron, Bay­er's Eylea nabs six months of pe­di­atric ex­clu­siv­i­ty as com­pe­ti­tion waits to en­ter the mar­ket

Paul Schloesser

Associate Editor

Re­gen­eron and Bay­er’s block­buster eye drug Eylea has been giv­en six months more pro­tec­tion from com­pe­ti­tion — now ex­tend­ing in­to the first half of 2024. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

GSK's Ze­ju­la-Jem­per­li com­bo in ovar­i­an can­cer hits pri­ma­ry end­point, miss­es on over­all sur­vival

A service from the Financial Times